Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) Profit After Tax (2017 - 2025)

Crinetics Pharmaceuticals has reported Profit After Tax over the past 9 years, most recently at -$122.8 million for Q4 2025.

  • Quarterly results put Profit After Tax at -$122.8 million for Q4 2025, down 52.39% from a year ago — trailing twelve months through Dec 2025 was -$465.3 million (down 55.93% YoY), and the annual figure for FY2025 was -$465.3 million, down 55.93%.
  • Profit After Tax for Q4 2025 was -$122.8 million at Crinetics Pharmaceuticals, up from -$130.1 million in the prior quarter.
  • Over the last five years, Profit After Tax for CRNX hit a ceiling of -$22.9 million in Q1 2021 and a floor of -$130.1 million in Q3 2025.
  • Median Profit After Tax over the past 5 years was -$54.2 million (2023), compared with a mean of -$62.5 million.
  • Biggest five-year swings in Profit After Tax: fell 20.3% in 2023 and later plummeted 69.33% in 2025.
  • Crinetics Pharmaceuticals' Profit After Tax stood at -$30.8 million in 2021, then crashed by 46.1% to -$45.0 million in 2022, then plummeted by 33.58% to -$60.1 million in 2023, then tumbled by 34.11% to -$80.6 million in 2024, then crashed by 52.39% to -$122.8 million in 2025.
  • The last three reported values for Profit After Tax were -$122.8 million (Q4 2025), -$130.1 million (Q3 2025), and -$115.6 million (Q2 2025) per Business Quant data.